Canagliflozin for advanced solid tumors in patients with or without diabetes
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have an advanced solid tumor that hasn't responded to standard treatment or for which no standard treatment exists, and your doctor thinks immunotherapy is an option.
- Your cancer can be measured on a CT scan.
- You are in fairly good health (ECOG score 0 or 1) and expected to live at least 3 months.
- You either have type 2 diabetes or no diabetes at all (but not type 1 diabetes).
- Your blood counts, kidney function, liver function, and heart function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
This trial tests a drug called tislelizumab (a type of immunotherapy) for people with advanced solid tumors that have stopped responding to standard treatments. The drug may help your immune system fight the cancer, but only if your tumor shows a specific genetic marker.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.